Abstract Number: PB2354
Meeting: ISTH 2020 Congress
Background: Previously, it was found that the development of metabolic syndrome (MS) is accompanied by hypercoagulation with the transition to thrombogenesis. It is shown that regulatory proline-containing peptides prevent thrombosis during the development of atherosclerotic changes in blood vessels.
Aims: To show the preventive antithrombotic effect of arginine and lysine-containing peptides in the development of MS.
Methods: Male Wistar rats were used in the experiments. Experiments were conducted in accordance with the principles of the European Convention (Strasbourg). In a model of MS rats caused by keeping animals on a high-calorie diet (HCD) for 6 weeks, intranasal within 7 days administration of peptides RKKRPGP and KKRRPGP was performed. After 20 h and 7 days samples of venous blood were analyzed for anticoagulant activity (APTT), enzymatic fibrinolytic activity (EFA), activity of tissue plasminogen activator (t-PA), euglobulin clot lysis time (ECLT), fibrindepolymerization activity (FDPA).
Results: In the blood of MS rats (control), a high degree of thrombogenesis was detected: APTT shortening by 50%, decrease in EFA, t-PA, ECLT, FDPA. 20 h after administration of peptides in the experimental rats an increase in fibrinolysis was found in comparison with the control: FDPA – by 70% (KKRRPGP), 206% (RKKRPGP), t-PA activity – by 24% ((RKKRPGP) or no change (KKRRPGP), APTT increased by 15% (KKRRPGP) and 25% (RKKRPGP). 7 days after the discontinuation of peptides at continuing of HCD, there was a preservation of increased anticoagulant and fibrinolytic activity of the blood and an even greater shortening of ECLT by 61-62% for both peptides.
Conclusions: Thus, when modeling MS in rats, arginine-and lysine-containing peptides had a complex effect on haemostatic system parameters, increasing the anticoagulant, fibrindepolymerization and fibrinolytic properties of blood plasma during 7 days of the experiment, which indicated their preventive positive antithrombotic effects in thrombogenesis.
Study was supported by RFBR 18-04-00260
To cite this abstract in AMA style:Lyapina L, Grigorjeva M, Obergan T, Shubina T, Myasoedov N, Andreeva L. Prevention of Thrombogenesis in the Development of Metabolic Syndrome [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/prevention-of-thrombogenesis-in-the-development-of-metabolic-syndrome/. Accessed October 1, 2023.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/prevention-of-thrombogenesis-in-the-development-of-metabolic-syndrome/